-
Epignostix launches CNS and sarcoma diagnostic tumor classifier applications
Heidelberg, Germany, January 22, 2025 Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces the successful launch of their CNS and sarcoma tumor classifiers- marking a substantial milestone in driving market development for their flagship indication, CNS tumor classification, and expansion to additional applications. Combining epigenetics […]
-
Heidelberg Epignostix appoints Helge Lubenow as CEO
Heidelberg, Germany, July 16, 2024 – Heidelberg Epignostix, a deeptech start-up committed to precision cancer diagnostics today announces the appointment of Helge Lubenow as CEO. She will be succeeding founder David Jones in the role who will continue to support Heidelberg Epignostix as Chief Scientific Officer. Helge Lubenow has almost 25 […]
-
DKFZ spin-off Epignostix raises €4.3m seed round to commercialize diagnostic tumor classifier
Heidelberg, Germany, July 2, 2024 – Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification. CARMA FUND I Capital GmbH […]